We retrospectively simulated the reduction of injected activity (1 vs. 2 MBq/kg, [<sup>18</sup>F]FDG) in 100 patients assessed for cognitive impairment with simultaneous PET/MRI imaging.
[<sup>18</sup>F]FDG, [<sup>11</sup>C]PiB, and [<sup>18</sup>F]AV-1451 PET Imaging of Neurodegeneration in Two Subjects With a History of Repetitive Trauma and Cognitive Decline.
We report the F-FDG and F-florbetapir dynamic PET images (early and delay phases) of an 83-year-old woman with cognitive impairment associated with visual hallucinations and parkinsonism due to probable DLB.
Next, we discuss how <sup>18</sup>F-FDG PET studies have advanced understanding of the relation between distinct brain regions and associated symptoms in Parkinson disease, including cognitive decline.
<b>Conclusion:</b> Independent-component analysis of <sup>18</sup>F-FDG PET data showed a gradual disruption of functional brain connectivity with progression of cognitive decline in AD.
Taken together, the current literature underscores the utility of <sup>18</sup>F-FDG PET for diagnostic evaluation of parkinsonism and the promising role of <sup>18</sup>F-FDG PET for assessment and risk stratification of cognitive impairment in PD.